Recent

% | $
Quotes you view appear here for quick access.

Waste Connections Inc. Message Board

Carolyn_Novice 305 posts  |  Last Activity: 14 hours ago Member since: Feb 3, 1999
  • carolyn_novice by carolyn_novice Aug 4, 2016 11:01 AM Flag

    San Mateo-based Visa, which has been an official sponsor of the Olympic Games for some time, is for the first time utilizing wearables for payment systems at this year’s games.

    Visa has collaborated on three new NFC-enabled wearables for payment systems, which include a watch, a nylon band and a ceramic ring, the company says. Visa, which is the only payment accepted at the Olympic Games other than cash, will have NFC-friendly pay stations at 4,000 locations throughout Olympic Park.

    “In our 30 years of sponsorship of the Olympic movement, this marks the first games where wearable technology and mobile technology will be widely implemented,” said Jim McCarthy, EVP, Innovation & Strategic Partnerships at Visa, on its website.

    Now that all the news is out, we need heavy volume and stock above $80 with strong closing for traders and investors to get on for long ride.

    News from Europe is good and interest rates will remain low for another year. UK cuts interest rates to 0.25% is very bullish for Visa.

    Good luck!

    Sincerely,
    Carolyn Novice

    Sentiment: Buy

  • At 10:25am, August 3, 2016, volume is 9.75 million, with the earning out why suck liquidation?

    Please wait and not buy in this liquidation.

    Good luck!
    Sincerely,
    Carolyn Novice

  • In June 2016, Pfizer announced that it completed its acquisition of Anacor for $99.25 in cash (without

    interest but subject to required withholding of taxes) per share of Anacor common stock, for a total

    transaction value, net of cash and cash equivalents, of approximately $5.2 billion.

    Pfizer announced in March 2016 that it entered into an accelerated share repurchase agreement with

    Goldman, Sachs & Co. (GS&Co.) to repurchase $5 billion of Pfizer’s common stock. Pursuant to the terms

    of the agreement, on March 10, 2016, Pfizer paid $5 billion to GS&Co. and received an initial delivery of

    approximately 136 million shares of Pfizer common stock from GS&Co. Upon settlement of the

    agreement in June 2016 and pursuant to the agreement's settlement terms, GS&Co. delivered

    approximately 18 million additional shares of Pfizer common stock to Pfizer. After giving effect to the

    accelerated share repurchase agreement, Pfizer's remaining share-purchase authorization was

    approximately $11.4 billion as of August 2, 2016.

    Good luck!
    Sincerely,
    Carolyn Novice

    Sentiment: Hold

  • Dur to 47 million shorts, and with the earning as well as Ex divided tomorrow, there is desire by professional to sell first and then cover to aviod paying dividend.

    Volume should be heavy this week, major news media CNBC, as well WSJ and Barron's will write and cover PFE, as it is part of Dow Jones stock.

    There is News MRK may buy Biogen, that can effect the entire drug group. Traders will take their clue ear the closing.

    Good luck!
    Carolyn Novice

    Sentiment: Hold

  • carolyn_novice carolyn_novice Aug 2, 2016 1:08 PM Flag

    You are wrong on dividend date. I think it is Aug 3, 2016, record date is Aug 6, 2016.

    Today's decline is due to index selling. And after nice run in the expectation of earning. Lot of stocks after good earning settle down and consolidate at lower level.

    We will know after this week how and where support is. I was unable to hear 10:00AM conference.

    Good luck!
    Sincerely,
    Carolyn Novice

    Sentiment: Hold

  • There will tug of war between Mutual Funds and Hedge funds to find a reason after the earnings. Each side trying find that part of news or future guidance to prove a point.

    Please wait till 10:00am and not rush to quick buy or sell. If there is a trend then it should last till end of this year, unless PFE decides to buy another company.

    In the end, Ler the Force be with you, will decide.

    Good luck!
    Sincerely,
    Carolyn Novice

    Sentiment: Strong Buy

  • At 11:30am volume 9,261,458 volume, 10 average volume is 15 million.

    Nice momentum and good base to move higher. Let us see near the close if traders take profits or stand back for a better opportunity after a few days.

    Good luck!
    Sincerely,
    Carolyn Novice

    Sentiment: Strong Buy

  • Earning is on August 5, 2016 before the opening. There is not enough volume to carry through the over head resistance.

    At 10:45 volume is 314,000 which is very good. Stock has been consolidating for a long time, we are approaching pivotal point.

    Will break though $57.50...$58.00 restistane with more than 2 million volume?

    Good luck!
    Sincerely,
    Carolyn Novice

    Sentiment: Buy

  • Volume at 10:15 very heavy 4.5 million.

    New high on high volume is vey bullish, with more than 45 million short interest.

    Earning tomorrow ...your guess is as good as mine.

    Good luck!
    Sincerely,
    Carolyn Novice

    Sentiment: Strong Buy

  • Pfizer Inc. (NYSE: PFE) is scheduled to reveal its second-quarter results on Tuesday as well. The consensus estimates call for $0.62 in EPS and $13.01 billion in revenue. Shares were trading at $36.89 on Friday’s close. The consensus price target is $39.34, and the 52-week range is $28.25 to $37.19.

    Drug group is strong, but besides earning it the future guideline on revenue and drugs in the pipeline.

    Volume on the first day of August will be key to what we can expect.

    Good luck!
    Sincerely,
    Carolyn Novice

    Sentiment: Buy

  • Nice volume and end of Second Quarter window Dressing. We can expect more than 5% up from these levels, after consolidation.

    Lot of news on AT&T this weekend.

    Good luck!

    Sincerely,

    Carolyn Novice

    Sentiment: Buy

  • Reply to

    Levels to watch

    by notsoobviousman1 Jul 29, 2016 2:42 PM
    carolyn_novice carolyn_novice Jul 29, 2016 3:03 PM Flag

    You are very professional and I am trader, this was a special advise from who is Novice and always remain.

    I will close my books soon with GILD and head to the beach.

    Have a nice weekend.

    Good luck!

    Sincerely,
    Carolyn Novice

    Sentiment: Strong Sell

  • Reply to

    Levels to watch

    by notsoobviousman1 Jul 29, 2016 2:42 PM
    carolyn_novice carolyn_novice Jul 29, 2016 2:55 PM Flag

    Please go YouTube and learn Basic Chart Reading, why tell others to hold when you keep loosing streak daily.

    Time to confess and cut your losses, tax losses this year for GiILD will be liquidation.

    A nod for the wise.
    Please take an action before market close and go to the Happy hour to find some sympathy.

    Good luck!

    Sincerely,
    Carolyn Novice

    Sentiment: Strong Sell

  • Try to have stop before new low soon.

    Good luck!
    SIncerely,
    Carolyn Novice

    Sentiment: Strong Sell

  • Reply to

    Script Analysis for GILD, ABBV & MRK

    by cointosser Jul 29, 2016 12:29 PM
    carolyn_novice carolyn_novice Jul 29, 2016 1:24 PM Flag

    You are barking at the wrong tree. Stocks acts like a barometer and thermometer. Market is forecasting that stocks, like MRK, PFE, NVO are moving closer to new high and away from new lows. Please ask why is GILD going south to Florida in this heat wave?

    Time to cut your losses, and find green pastures.

    Good luck!
    Sincerely,
    Carolyn Novice

    Sentiment: Strong Sell

  • carolyn_novice by carolyn_novice Jul 29, 2016 7:17 AM Flag

    Now we know why GILD is near low and MRK near high.

    Please read the earning news and European approval on MRK.

    Good luck!
    Sincerely,
    Carolyn Novice

    Sentiment: Strong Sell

  • carolyn_novice by carolyn_novice Jul 29, 2016 7:09 AM Flag

    European Commission Grants Marketing Authorisation for MSD’s ZEPATIER™ (elbasvir/grazoprevir) for the Treatment of Chronic Hepatitis C Infection
    Jul 15, 2016)3:

    In Phase 3 Clinical Trials, ZEPATIER Achieved High Cure (SVR) Rates Across Diverse Populations of Patients With Chronic Hepatitis C, Including Those With Compensated Cirrhosis, Renal Impairment or on Opioid Agonist Therapy
    Merck
    1 minute ago
    
    KENILWORTH, N.J.--(BUSINESS WIRE)--

    MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA (MRK)) today announced that the European Commission has approved ZEPATIER™ (elbasvir/grazoprevir) with or without ribavirin (RBV) for the treatment of chronic hepatitis C virus (HCV) genotype (GT) 1 or GT4 infection in adults. ZEPATIER is MSD’s once-daily, fixed-dose combination tablet containing the NS5A inhibitor elbasvir (50mg) and the NS3/4A protease inhibitor grazoprevir (100mg). This approval allows marketing of ZEPATIER tablets in the 28 countries that are members of the European Union, as well as European Economic Area members, Iceland, Liechtenstein and Norway. MSD continues to work to supply the EU market, with product launches estimated to begin between the fourth quarter of 2016 and the first quarter of 2017. Product launches are expected to continue across the EU through 2017.

    Sentiment: Strong Buy

  • Let us the guidance.

    Good luck!
    Sincerely,
    Carolyn Novice

    Sentiment: Buy

  • carolyn_novice by carolyn_novice Jul 29, 2016 7:00 AM Flag

    Merck beats 2Q profit forecasts
    Merck tops 2Q net income expectations, meets revenue forecasts
    Associated Press
    4 minutes ago
    

    KENILWORTH, N.J. (AP) _ Merck & Co. (MRK) on Friday reported second-quarter earnings of $1.21 billion.

    The Kenilworth, New Jersey-based company said it had profit of 43 cents per share. Earnings, adjusted for costs related to mergers and acquisitions and restructuring costs, came to 93 cents per share.

    The results exceeded Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for earnings of 92 cents per share.

    The pharmaceutical company posted revenue of $9.84 billion in the period, which matched Street forecasts.

    Merck expects full-year earnings in the range of $3.67 to $3.77 per share, with revenue in the range of $39.1 billion to $40.1 billion.

    Merck shares have risen 11 percent since the beginning of the year, while the Standard & Poor's 500 index has risen 6 percent. The stock has risen nearly 2 percent in the last 12 months.

  • Merck beats by $0.02, beats on revenue
    Merck (NYSE:MRK): Q2 EPS of $0.93 beats by $0.02.Revenue of $9.84B (+0.5% Y/Y) beats by $60M.Press Release
    Now read: Merck Calls Time On U.S. Allergy Market

    Let us see if this news on earning helps it to move higher with volume.

    Good luck!
    Sincerely,
    Carolyn Novice

    Sentiment: Buy

WCN
76.64-0.80(-1.03%)Aug 26 4:02 PMEDT